There are several treatment options available for spinal muscular atrophy (SMA), a rare genetic condition characterized by progressive muscle weakness and wasting. The disease mainly affects motor ...
The next level to watch is the 100-day Simple Moving Average (SMA) at 0.6425, followed by the weekly top at 0.6549 (November 25), and finally the 200-day SMA at 0.6553. On the downside ...
Evrysdi is the only non-invasive disease-modifying treatment for SMA. The 5 mg Evrysdi tablet can either be swallowed whole or dispersed in water. “Evrysdi has robust potential to modify the SMA ...